Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongfengkang is a natural medicine candidate developed by the Qingdao Haichuan Innovative Natural Medicine Research Center for the treatment of primary acute gouty arthritis. Derived from traditional Chinese medicinal knowledge but developed as a modern pharmaceutical, it aims to address the intense inflammation and pain associated with acute gout flares. The drug's mechanism involves the suppression of inflammatory cytokines and the potential regulation of uric acid levels. It has undergone clinical evaluation in China, reaching Phase III trials, where it demonstrated efficacy in reducing joint swelling and pain scores in patients with acute gouty attacks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongfengkang.